Oncology and Carcinogenesis articles for Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 238

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 0.03
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.03
3 2.46
Pancreas Cancer Risk During Intraductal Papillary Mucinous Neoplasm Surveillance - A SEER-Based Comparison. 1.00
Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. 1.00
Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. 0.46
9 0.78
A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma 0.04
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.08
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) 0.07
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma 0.31
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.03
Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study 0.07
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.04
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma 0.12
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. 0.02
1 0.72
Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study 0.72
13 4.06
Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer 0.22
Cancer type-specific variation in patterns of driver alterations across 50,000 tumors 1.00
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence 0.02
Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression 0.65
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.01
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer 0.07
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.64
Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer 0.40
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases 0.00
Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy 0.00
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models 0.09
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma 0.00
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer 0.95
10 2.56
Integrated Spatial Analysis Reveals the Molecular Landscape of Ovarian Precancerous Lesions 0.07
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules 0.03
Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer 0.76
The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer 0.16
Quantitative Cell Type–Specific Immunopeptidome Analysis of Macrophage and Tumor Coevolution Reveals Therapeutic MHC-I Peptides in Glioblastoma 0.09
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma 0.09
PAX3-FOXO1 Drives Targetable Cell State–Dependent Metabolic Vulnerabilities in Rhabdomyosarcoma 0.82
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer 0.07
RIT1 Drives Oncogenic Transformation and Is an Actionable Target in Lung Adenocarcinoma 0.43
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. 0.06
7 1.09
Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis 0.00
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers 0.03
Disrupted molecular glue complex drives RAS inhibitor resistance 0.51
A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth suppression 0.08
pTα enhances mRNA translation and potentiates CAR T cells for solid tumor eradication 0.42
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers 0.05
Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis 0.00
1 0.44
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia 0.44
1 0.17
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICU. 0.17
2 1.19
Disruption of WNT/Notch signaling in pancreatic cancer reveals tumors depend on the intricate equilibrium of malignant cell states 0.49
Ferroptosis induces heterogeneous death profiles that are controlled by lysosome rupture 0.69
2 0.22
Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer 0.17
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.05
1 0.60
Separable roles for Microprocessor and its cofactors, ERH and SAFB1/2, during microRNA cluster assistance 0.60
1 0.03
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.03
5 0.22
Agonistic anti-CD40 antibody treatment converts resident regulatory T cells into activated type 1 effectors within the tumor microenvironment 0.00
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.00
IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 0.00
IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy 0.04
A fungal-derived adjuvant amplifies the antitumoral potency of Bacillus Calmette-Guérin via reprogramming granulopoiesis 0.18
1 0.02
Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project 0.02
3 1.13
Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy 0.76
Gene Expression Profile–Based Test to Predict Melanoma Sentinel Node Status 0.09
Gauging the Magnitude of Missed Opportunity for Ovarian Cancer Prevention 0.28
1 0.90
Activity-based probes and chemical proteomics uncover the biological impact of targeting HMG-CoA Synthase 1 in the mevalonate pathway 0.90
1 0.08
Telomeric SUMO level influences the choices of APB formation pathways and ALT efficiency 0.08
1 1.00
Comparable Outcomes of Differentiated Thyroid Cancer in Immunocompromised Versus Immunocompetent Patients 1.00
6 0.81
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.02
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome 0.07
Interlocking host and viral cis-regulatory networks drive Merkel cell carcinoma 0.03
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer 0.09
BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature-positive castration-resistant prostate cancer 0.57
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer 0.02
17 0.68
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial 0.03
Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. 0.07
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. 0.03
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. 0.06
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.06
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.04
PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. 0.03
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.02
Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study. 0.05
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003. 0.03
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.02
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.04
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. 0.09
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.02
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. 0.04
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.02
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.04
2 0.50
Sympathetic axonogenesis promotes adenoid cystic carcinoma progression 0.50
Tumor cell heterogeneity drives spatial organization of the intratumoral immune response 0.00
3 2.07
Lobectomy improves disease-free survival over sublobar resection for high-risk stage IA non−small cell lung cancer 1.00
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.07
Surgical Outcomes Using Three-Dimensional Image Simulation for Segmentectomy Planning in Patients with Stage IA1-2 Non-Small Cell Lung Cancer 1.00
17 4.96
Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium 0.15
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer 0.50
NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in pancreatic cancer 0.91
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience 0.13
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.04
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancer 0.42
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial 0.13
Prognostic value of visually and computationally-assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030) 0.05
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.11
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (alliance) 0.03
Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer 0.52
Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study 0.09
The impact of eligibility criteria on KRASG12C inhibitor trials in patients with NSCLC 0.19
Mortality after colorectal cancer among survivors of childhood cancer 0.19
Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort 0.03
Unveiling non-small cell lung cancer treatment effect heterogeneity: a comparative analysis of statistical methods 0.63
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma 0.86
4 3.47
ER-tethering directs TREX1 penetration of a BAF-dependent barrier at micronuclei 0.85
Endocytosis is essential for cysteine-deprivation-induced ferroptosis 0.86
HIF-independent oxygen sensing via KDM6A regulates ferroptosis 0.76
Chromosomal tethering and mitotic transcription promote ecDNA nuclear inheritance 1.00
12 5.45
Early fibrotic niches establish tumour-permissive microenvironments 0.25
A glucocorticoid–FAS axis controls immune evasion during metastatic seeding 0.00
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.50
Critical role for a high-plasticity cell state in lung cancer 0.83
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.01
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.04
NSD2 targeting reverses plasticity and drug resistance in prostate cancer 0.17
Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome 0.97
Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA 0.95
Mechanical confinement governs phenotypic plasticity in melanoma 0.74
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.04
Metabolic adaptations direct cell fate during tissue regeneration 0.94
1 0.59
p53 increases phospholipid headgroup scavenging in senescence 0.59
29 3.68
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers 0.15
Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy 0.02
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.00
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER HER2 locally-advanced or metastatic breast cancer 0.03
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.06
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target 0.11
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in G12C-mutant advanced solid tumors: a first-in-human study 0.04
A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance 0.04
Tumor-informed circulating tumor DNA stratifies recurrence risk and survival in anal squamous cell carcinoma 0.74
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC 0.06
Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15 0.03
Site-saturation functional screens identify PALB2 missense variants associated with increased breast cancer risk 0.02
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.04
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer 0.88
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.03
Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer 0.10
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer 0.00
The /EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs 0.15
EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma 0.02
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci 0.05
Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors 0.05
CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12 0.57
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer 0.24
Structure and function of the human apoptotic scramblase Xkr4 0.01
Structure of CFTR bound to ()-BPO-27 unveils a pore-blockage mechanism 0.06
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.02
ST2/IL-33 axis blockade inhibits regulatory T cell cytotoxicity towards CD8 T cells in the leukemic niche 0.14
Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny 0.00
A macrophage-predominant immunosuppressive microenvironment and therapeutic vulnerabilities in advanced salivary gland cancer 0.04
10 3.75
High-resolution single-cell mapping of clonal hematopoiesis and structural variation in aplastic anemia 0.02
CDK4/6 inhibition mitigates chemotherapy-induced expansion of -mutant clonal hematopoiesis 0.44
Genomic evolution of pancreatic cancer at single-cell resolution 0.68
Passenger mutations link cellular origin and transcriptional identity in human lung adenocarcinomas 0.13
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer 0.38
Cellular states associated with metastatic organotropism and survival in patients with pancreatic ductal adenocarcinoma 0.04
ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L 1.00
Temporal genomic dynamics shape clinical trajectory in multiple myeloma 0.20
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.02
Longitudinal and multisite sampling reveals mutational and copy number evolution in tumors during metastatic dissemination 0.83
18 1.47
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial 0.02
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial 0.04
Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial 0.03
Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial 0.02
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial 0.87
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial 0.04
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.02
Abemaciclib in meningiomas with somatic or CDK pathway alterations: the phase 2 Alliance A071401 trial 0.03
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.03
CD4 T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy 0.00
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial 0.06
Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial 0.05
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.04
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.02
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results 0.07
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.05
2 0.45
An ultrasmall core–shell silica nanoparticle improves antitumour immunity and survival by remodelling suppressive melanoma microenvironments 0.06
Machine perception liquid biopsy identifies brain tumours via systemic immune and tumour microenvironment signature 0.39
1 0.15
A local sympathetic-immune axis inhibits melanoma growth in mice by dictating adrenergic control 0.15
10 2.39
Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade 0.00
Microglial fructose metabolism is essential for glioblastoma growth 0.07
ARP2/3 complex mediates the neuropathology of PTEN-deficient human neural cells downstream of mTORC1 and mTORC2 hyperactivation 0.06
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers 0.73
Occludin acts as a dynein adaptor regulating permeability and collateral angiogenesis 0.04
Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy 0.04
Targeting orthotopic and metastatic pancreatic cancer with allogeneic stem cell–engineered mesothelin-redirected CAR-NKT cells 0.00
Single-cell sequencing uncovers sensory neuron–mediated CGRP signaling as a driver of sarcoma progression 0.04
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer 0.78
BRCA2 reversion mutation–independent resistance to PARP inhibition through impaired DNA prereplication complex function 0.64
3 2.50
Abbreviated MRI for the Evaluation of Treatment Response in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer. 0.69
Optimizing Colorectal Liver Metastasis Ablation through Metabolic Imaging, Margin Assessment, and Biopsy (The OPTABLATE Prospective Trial). 0.96
Adaptive Breast MRI Scanning Using AI. 0.85
3 0.80
Sensitive CAR T cells redefine targetable CD70 expression in solid tumors 0.66
Macrophage-derived oncostatin M repairs the lung epithelial barrier during inflammatory damage 0.14
In vivo CAR T cell generation to treat cancer and autoimmune disease 0.00
6 1.01
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma 0.61
<atl>Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and iBAP1/i loss</atl> 0.01
Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia 0.04
Phenotypic discovery and therapeutic evaluation of an ITGA3B1-targeting antibody-drug conjugate for bladder cancer 0.00
Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators 0.33
Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases 0.00
4 0.77
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers 0.01
Engineering CAR T cells to secrete VEGF-neutralizing scFvs enhances antitumor activity against solid tumors 0.00
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses 0.12
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers 0.64
3 0.09
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial 0.05
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial 0.01
9 1.35
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial 0.03
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study 0.94
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.06
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 0.06
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study 0.07
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.05
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis 0.07
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study 0.06
14 0.54
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer 0.05
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer 0.04
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.02
Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors 0.06
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.02
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.03
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.03
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy 0.07
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.04
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.04
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.03
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.04

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.